GlassScriptPhysician profile
James Liadis
NPI 1770825127
$1,790.91
in general payments reported to CMS, 2019-2025
15 companies · $155 in 2025
The $155 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $278 · 2021: $47.72 · 2022: $108 · 2023: $80.56 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $934.13 | 2019-2025 | Intracept |
| Spr Therapeutics, INC | $339.35 | 2019-2023 | Sprint Pns System |
| Amgen INC. | $145.98 | 2019-2021 | |
| Flowonix Medical Incorporated | $113.93 | 2019 | |
| Abbvie INC. | $95.15 | 2021-2023 | |
| Avanos Medical | $24.70 | 2019 | |
| Lundbeck LLC | $24.37 | 2022 | |
| Allergan, INC. | $17.74 | 2019 | |
| Nalu Medical, INC. | $15.54 | 2023 | Nalu Neurostimulation System |
| Emd Serono, INC. | $15.13 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.62 | 2022 | |
| Biodelivery Sciences International, INC. | $13.12 | 2021 | |
| Saol Therapeutics INC. | $11.19 | 2019 | |
| Lilly USA, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Liadis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.